12/24
10:06 am
gild
Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise [Yahoo! Finance]
Low
Report
Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise [Yahoo! Finance]
12/24
07:27 am
gild
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration [Yahoo! Finance]
Low
Report
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration [Yahoo! Finance]
12/22
04:05 pm
gild
Gilead Sciences to Present at Upcoming Investor Conference
Low
Report
Gilead Sciences to Present at Upcoming Investor Conference
12/22
11:03 am
gild
Biopharma climbs higher as 9 drugmakers ink ‘pandering' drug price deals with Trump [Yahoo! Finance]
Low
Report
Biopharma climbs higher as 9 drugmakers ink ‘pandering' drug price deals with Trump [Yahoo! Finance]
12/22
11:03 am
gild
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 [Yahoo! Finance]
Low
Report
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 [Yahoo! Finance]
12/22
08:23 am
gild
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes [Yahoo! Finance]
Low
Report
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes [Yahoo! Finance]
12/22
08:00 am
gild
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Low
Report
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
12/22
02:33 am
gild
Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer [Yahoo! Finance]
Low
Report
Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer [Yahoo! Finance]
12/19
04:09 pm
gild
Why Gilead Sciences (GILD) Stock Is Up Today [Yahoo! Finance]
Low
Report
Why Gilead Sciences (GILD) Stock Is Up Today [Yahoo! Finance]
12/19
02:50 pm
gild
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans [Yahoo! Finance]
Low
Report
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans [Yahoo! Finance]
12/19
02:21 pm
gild
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
Low
Report
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
12/18
08:46 am
gild
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance [Yahoo! Finance]
Low
Report
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance [Yahoo! Finance]
12/18
08:30 am
gild
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
Low
Report
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
12/15
08:42 am
gild
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial [Yahoo! Finance]
Low
Report
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial [Yahoo! Finance]
12/15
08:30 am
gild
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Low
Report
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
12/15
07:02 am
gild
Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at Wolfe Research.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at Wolfe Research.
12/13
12:51 pm
gild
Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)? [Yahoo! Finance]
Low
Report
Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)? [Yahoo! Finance]
12/12
09:21 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Morgan Stanley from $147.00 to $151.00. They now have an "overweight" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Morgan Stanley from $147.00 to $151.00. They now have an "overweight" rating on the stock.
12/10
11:33 am
gild
Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) [Yahoo! Finance]
Low
Report
Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) [Yahoo! Finance]
12/10
09:21 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at HSBC Holdings plc from $110.00 to $133.00. They now have a "hold" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at HSBC Holdings plc from $110.00 to $133.00. They now have a "hold" rating on the stock.
12/10
09:21 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wells Fargo & Company from $145.00 to $150.00. They now have an "overweight" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wells Fargo & Company from $145.00 to $150.00. They now have an "overweight" rating on the stock.
12/9
08:30 am
gild
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
Low
Report
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
12/9
08:11 am
gild
Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at UBS Group AG to a "hold" rating.
Low
Report
Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at UBS Group AG to a "hold" rating.
12/7
08:00 am
gild
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
Low
Report
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
12/7
03:37 am
gild
Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates [Yahoo! Finance]
Low
Report
Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates [Yahoo! Finance]